Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges  

作　　者：Yunlong Shan Mengying Zhang Enxiang Tao Jing Wang Ning Wei Yi Lu Qing Liu Kun Hao Fang Zhou Guangji Wang 

机构地区：[1]Key Laboratory of Drug Metabolism and Pharmacokinetics,Haihe Laboratory of Cell Ecosystem,State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing,China [2]Jiangsu Renocell Biotech Co.Ltd.,Nanjing,China

出　　处：《Signal Transduction and Targeted Therapy》2024年第10期4314-4340,共27页信号转导与靶向治疗（英文）

基　　金：National Natural Science Foundation of China(82104184,82073928,82373949);Leading Technology Foundation Research Project of Jiangsu Province(BK20192005);the Haihe Laboratory of Cell Ecosystem Innovation Fund(22HHXBSS00005);Nanjing Scientific and Technological Special Project for Life and Health(202110006);“Double First-Class”University Project(CPU2018GF01,China);Jiangsu Province“333”project,China;and the Fundamental Research Funds for the Central Universities(2632023TD03).

摘　　要：Over the past two decades,mesenchymal stem/stromal cell(MSC)therapy has made substantial strides,transitioning from experimental clinical applications to commercial products.MSC therapies hold considerable promise for treating refractory and critical conditions such as acute graft-versus-host disease,amyotrophic lateral sclerosis,and acute respiratory distress syndrome.Despite recent successes in clinical and commercial applications,MSC therapy still faces challenges when used as a commercial product.Current detection methods have limitations,leaving the dynamic biodistribution,persistence in injured tissues,and ultimate fate of MSCs in patients unclear.Clarifying the relationship between the pharmacokinetic characteristics of MSCs and their therapeutic effects is crucial for patient stratification and the formulation of precise therapeutic regimens.Moreover,the development of advanced imaging and tracking technologies is essential to address these clinical challenges.This review provides a comprehensive analysis of the kinetic properties,key regulatory molecules,different fates,and detection methods relevant to MSCs and discusses concerns in evaluating MSC druggability from the perspective of integrating pharmacokinetics and efficacy.A better understanding of these challenges could improve MSC clinical efficacy and speed up the introduction of MSC therapy products to the market.

关 键 词：CHARACTERISTICS TRANSLATIONAL PRECISE 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]